Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Your search for oral corticosteroids returned 51 results
Findings may help with decision-making in this high-risk patient population.
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Ascorbic acid level testing confirmed severe deficiency (<0.1mg/dL).
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
Clinical practice guideline addresses 6 emerging questions around COPD management.
Topical glucocorticosteroids recommended over no treatment.
High doses of inhaled corticosteroids were associated with lower levels of eosinophils, which may interfere with the recommendation of some monoclonal antibodies in asthma treatment.